{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:12:19Z","timestamp":1761513139701},"reference-count":21,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The Global Cancer Genomics Consortium (GCGC) is an international collaborative platform that amalgamates cancer biologists, cutting-edge genomics, and high-throughput expertise with medical oncologists and surgical oncologists; they address the most important translational questions that are central to cancer research and treatment. The annual GCGC symposium was held at the Advanced Centre for Treatment Research and Education in Cancer, Mumbai, India, from November 9 to 11, 2011. The symposium showcased international next-generation sequencing efforts that explore cancer-specific transcriptomic changes, single-nucleotide polymorphism, and copy number variations in various types of cancers, as well as the structural genomics approach to develop new therapeutic targets and chemical probes. From the spectrum of studies presented at the symposium, it is evident that the translation of emerging cancer genomics knowledge into clinical applications can only be achieved through the integration of multidisciplinary expertise. In summary, the GCGC symposium provided practical knowledge on structural and cancer genomics approaches, as well as an exclusive platform for focused cancer genomics endeavors. Cancer Res; 72(15); 3720\u20134. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-12-1054","type":"journal-article","created":{"date-parts":[[2012,5,25]],"date-time":"2012-05-25T10:47:44Z","timestamp":1337942864000},"page":"3720-3724","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine"],"prefix":"10.1158","volume":"72","author":[{"name":"The Global Cancer Genomics Consortium","sequence":"first","affiliation":[]}],"member":"1086","published-online":{"date-parts":[[2012,7,31]]},"reference":[{"key":"2022061703510523200_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"2022061703510523200_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2022061703510523200_bib3","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1093\/hmg\/ddi113","article-title":"Cancer epigenetics","volume":"14","author":"Laird","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2022061703510523200_bib4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"2022061703510523200_bib5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1126\/science.1204040","article-title":"Exploring the genomes of cancer cells: progress and promise","volume":"331","author":"Stratton","year":"2011","journal-title":"Science"},{"key":"2022061703510523200_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome - biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2022061703510523200_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrg2484","article-title":"RNA-Seq: a revolutionary tool for transcriptomics","volume":"10","author":"Wang","year":"2009","journal-title":"Nat Rev Genet"},{"key":"2022061703510523200_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nmeth.1613","article-title":"Computational methods for transcriptome annotation and quantification using RNA-seq","volume":"8","author":"Garber","year":"2011","journal-title":"Nat Methods"},{"key":"2022061703510523200_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nm.2305","article-title":"Cancer epigenetics reaches mainstream oncology","volume":"17","author":"Rodriguez-Paredes","year":"2011","journal-title":"Nat Med"},{"key":"2022061703510523200_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2011.121","article-title":"Predictive biomarkers: a paradigm shift towards personalized cancer medicine","volume":"8","author":"La Thangue","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061703510523200_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2174\/156800909788166529","article-title":"Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine","volume":"9","author":"Germano","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"2022061703510523200_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/nbt1204supp-DC31","article-title":"Indian biotechnology\u2013rapidly evolving and industry led","volume":"22","author":"Kumar","year":"2004","journal-title":"Nat Biotechnol"},{"key":"2022061703510523200_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.cell.2005.11.018","article-title":"Bioscience in India: times are changing","volume":"123","author":"Dhawan","year":"2005","journal-title":"Cell"},{"key":"2022061703510523200_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/srep00264","article-title":"Transcriptomic landscape of breast cancers through mRNA sequencing","volume":"2","author":"Eswaran","year":"2012","journal-title":"Sci Rep"},{"key":"2022061703510523200_bib15","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/nmeth.1374","article-title":"Computational methods for discovering structural variation with next-generation sequencing","volume":"6","author":"Medvedev","year":"2009","journal-title":"Nat Methods"},{"key":"2022061703510523200_bib16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"2022061703510523200_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2010.11.009","article-title":"Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing","volume":"18","author":"Fedorov","year":"2011","journal-title":"Chem Biol"},{"key":"2022061703510523200_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/187152012798764705","article-title":"Atypical GTPases as drug targets","volume":"12","author":"Soundararajan","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"key":"2022061703510523200_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12282-009-0096-x","article-title":"Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer","volume":"16","author":"Toi","year":"2009","journal-title":"Breast Cancer"},{"key":"2022061703510523200_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10585-011-9438-0","article-title":"Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors","volume":"29","author":"Casimiro","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"2022061703510523200_bib21","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2010.33.0738","article-title":"Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial","volume":"29","author":"Badwe","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/15\/3720\/2670440\/3720.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/15\/3720\/2670440\/3720.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T12:57:52Z","timestamp":1655470672000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/72\/15\/3720\/575849\/The-Global-Cancer-Genomics-Consortium-Interfacing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,31]]},"references-count":21,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2012,7,31]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-12-1054","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,31]]}}}